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Abstract
Fractionation of the EtOH extract from aerial parts of Baccharis uncinella C. DC. (Asteraceae) led to isolation of caffeic and
ferulic acids, which were identified from spectroscopic and spectrometric evidence. These compounds exhibit antioxidant and
anti-inflammatory properties and have been shown to be effective in the prevention/treatment of metabolic syndrome. This study
investigated whether the combined treatment of caffeic and ferulic acids exhibits a more significant beneficial effect in a mouse
model with metabolic syndrome. The combination treatment with caffeic and ferulic acids was tested for 60 days in C57 mice
kept on a high-fat (40%) diet. The data obtained indicated that treatment with caffeic and ferulic acids prevented gain in body
weight induced by the high-fat diet and improved hyperglycemia, hypercholesterolemia and hypertriglyceridemia. The
expression of a number of metabolically relevant genes was affected in the liver of these animals, showing that caffeic and
ferulic acid treatment results in increased cholesterol uptake and reduced hepatic triglyceride synthesis in the liver, which is a
likely explanation for the prevention of hepatic steatosis. In conclusion, the combined treatment of caffeic and ferulic acids
displayed major positive effects towards prevention of multiple aspects of the metabolic syndrome and liver steatosis in an
obese mouse model.
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Introduction
Metabolic syndrome is a prothrombotic and proinflam-
matory state characterized by visceral obesity, insulin
resistance, dyslipidemia and hypertension (1). As a result
of increased synthesis and uptake of cholesterol and
triglycerides from plasma as well as reduction in the export
of these lipids to the circulation (2,3), patients with metabolic
syndrome frequently exhibit steatosis and non-alcoholic
fatty liver disease (2).
Given that metabolic syndrome affects millions of
individuals worldwide, there is increased interest in the
development of molecules that can mitigate the metabolic
consequences of obesity and liver disease. In this regard,
caffeic (CA) and ferulic (FA) acids are natural organic
compounds present in large amounts in the aerial parts of
Baccharis uncinella C. DC. (Asteraceae) (4). These com-
pounds function as key intermediate molecules in the
biosynthesis of lignin, one of the principal components
of plant biomass and its residues (5), and exhibit pro-
mising beneficial effects on metabolism when used in
experimental models of metabolic syndrome. For exam-
ple, treatment with CA has been reported to improve
hyperglycemia and hepatic steatosis in animals kept on a
high calorie diet, but obesity, hypertriglyceridemia and
hypercholesterolemia were not always prevented (6–9). In
addition, multiple studies indicate that treatment with CA
improves dyslipidemia and minimizes fasting hyperglyce-
mia, but does not always prevent diet-induced obesity
(10–13).
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Both CA and FA molecules only exhibit partial beneficial
effects on metabolism; therefore, we investigated whether
combined treatment with CA and FA could present a thera-
peutic advantage in the treatment of metabolic syndrome.
Our results show that this combined approach with mice
kept on a high-fat diet (HFD) successfully prevents obesity,
dyslipidemia and liver steatosis.
Material and Methods
Plant material
Aerial parts of B. uncinella C. DC. were collected from
Campos de Jordão, São Paulo State, Brazil in 2005.
Botanical identification was made by Prof. Dr. Oriana A.
Fávero (UPM). A voucher specimen (number SP382050)
has been deposited at the Herbario da Prefeitura
Municipal de São Paulo (PMSP), São Paulo, Brazil.
Instruments
Sephadex LH-20 (Amersham Biosciences, England)
was used for column chromatographic separation while
silica gel 60 PF254 (Merck, USA) was used for analytical TLC
(0.25 mm). The 1H and 13C NMR spectra were recorded on
a Bruker Ultrashield Avance II spectrometer operating at 300
and 75 MHz, respectively. Spectra were performed with
CD3OD or DMSO-d6 (Tedia, Brazil) using the residual
solvent peak as the internal standard. The chemical shifts (d)
are given in parts per million and coupling constants (J) in
Hz. LRESIMS was measured with a Micromass Platform
mass spectrometer, operating in negative mode. Semi-
preparative high-performance liquid chromatography was
performed using a Dionex Ultimate 3000 chromatograph
equipped with a Luna C18 column (250 10 mm, 5 mm id;
Phenomenex, USA) and a UVD-DAD detector.
Extraction and isolation
Dried and powdered aerial parts of B. uncinella (400 g),
popularly known as vassoura, were extracted using EtOH
at room temperature. After solvent elimination under
reduced pressure, 14 g of crude extract was obtained.
Part of this material (5 g) was re-suspended in EtOAc
and extracted using NaOH 4% until pH 10 was attained.
The alkaline phase was made acidic (pH 1) with HCl 2%
and extracted with EtOAc. After drying with Na2SO4
and concentrating under reduced pressure, the EtOAc
phase (2 g) was chromatographed over Sephadex LH-20
(30 2 cm), using MeOH as the eluant. This procedure
provided 42 fractions (15 mL each), which were pooled into
four groups (I–IV), after TLC analysis. Part of group II
(120 mg) was purified by semi-preparative high-perfor-
mance liquid chromatography (MeOH:H2O 7:3, flow rate at
1 mL/min) to produce CA (39 mg) and FA (71 mg).
Animals and treatment
Male 8-week-old C57/BL6 mice were kept at 24°C with
a 12:12-h light:dark cycle starting at 06:00 h and housed in
standard plastic cages with 5 mice per cage. Food and
water was provided ad libitum. All procedures were
approved by the local Institutional Animal Care and Use
Committee (CEAU/UPM #086/08/2011), according to the
International Guiding Principles for Biomedical Research
Involving Animals.
Eight animals were fed with either a chow diet
(1.8 kcal/g) or a high fat diet (7.52 kcal/g) (Table 1) and
after 20 days, glucose tolerance, cholesterolemia and
triglyceridemia were assessed to verify if the mice on HFD
presented the abnormalities of metabolic syndrome. Once
it was confirmed that the animals exhibited metabolic
syndrome, we initiated daily subcutaneous injections of
CA (0.9 mg  kg–1  day–1) combined with FA (50 mg  kg–1 
day–1) for more than 40 days. Food consumption and body
weight were measured daily. By the end of the protocol on the
60th day, animals were lightly anesthetized with urethane
(1200 mg/kg) and killed by decapitation to obtain serum and
tissue samples that were immediately snap frozen for further
analyses.
Intraperitoneal glucose tolerance test
The animals were fasted overnight and glucose (2 g/kg)
was injected intraperitoneally between 09:00 and 10:00 h.
Blood samples were collected from the tail vein at the
indicated times after the glucose load and glycemia were
immediately determined on a glucose analyzer (LifeScan,
Inc., USA).
Blood chemistry
Total serum cholesterol and triglycerides were assessed
via enzymatic methods using a commercial kit (Cholesterol
Liquiform and Triglicérides Liquiform, Labtest, Brasil). Subse-
quently, the absorbance of the samples was measured with
the NanoDrop 2000c (Thermo Scientific, USA), at wave-
lengths of 500 and 505 nm, respectively.
Analysis of mRNA
The animal livers were dissected and total RNA
extracted using Trizols (Life Technologies Inc., USA),
according to the manufacturer’s instructions, and quanti-
fied by spectrophotometry (Nanodrop 2000c). For the
reverse transcriptase reaction, 1.0 mg of total RNA was
Table 1. Composition of chow diet (Control) and high-fat diet
(HFD).
Components Control HFD
Protein (%) 22 20
Carbohydrates (%) 49 25
Fat (%) 4 40
Others (%) 25 15
Calories (kcal  g–1) 1.7 5.4
Others: vitamins, minerals and fiber.
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used in the SuperScriptt First-Strand Synthesis System
for reverse transcription-polymerase chain reaction (Life
Technologies Inc.) with a Mastercycler thermocycler
(Eppendorf, Germany). Based on the reaction efficiency,
approximately 120 ng of cDNA was used for amplification.
Quantitative real time PCR was performed using Quanti-
Tectt SYBRs Green PCR (Qiagen, Valencia CAF with
program ECO by Ilumina, USA). The cycle conditions
were: 15 min at 94°C, 15 s at 94°C, 30 s at 60°C, and 30 s
at 72°C for 50 cycles followed by the melting curve
protocol to verify the specificity of amplicon generation.
Gene expression was determined by the DDCt method as
described by Christoffolete (14). The housekeeping gene
GAPDH and beta-actin were used as internal reference.
Primer sequences are available upon request. The target
genes were related to cholesterol (LDL-R, SREBP 2, LXR,
ACAT-1, HMG-CoA), triglycerides (SREBP-1c, ChREBP,
FAS, DGAT 2, MTTP, ATGL) and glucose (G6pase, PPAR-a)
metabolism.
Western blotting
Brown adipose tissue was processed for mitochondrial
isolation. Mitochondrial proteins were then size-fractionated
by 12% SDS-PAGE and probed with UCP1 (Santa Cruz,
Biotechnology, USA) (15).
Histology
After dissection, tissues (liver and white adipose
tissue) were immersed in buffered formaldehyde solution
(10%) and fixed for 24 h. Paraffin-embedded tissues were
sectioned and processed as described for staining with
hematoxylin-eosin or Masson’s trichrome. The area of
adipocytes was estimated by analysis of images photo-
graphed at 100 amplification with optical microscopy
(Axioskop 2 plus, Zeiss, Germany). The images were ana-
lyzed by the program AxionVision Rel. 4.6, which esti-
mated the area of 40 adipocytes per animal.
Statistical analysis
The statistical analyses were done by one-way
analysis of variance followed by the Student-Newman-
Keuls post-test when Po0.05. For all tests, Po0.05 was
considered to be statistically significant. Data are reported
as means±SE.
Results
Characterization of caffeic and ferulic acids
Isolated compounds from aerial parts of B. uncinella
were characterized as derivatives of cinnamic acid by
analysis of their 1H NMR spectra. Typical signals of the
trans-alkene system of C6-C3 derivatives at d 7.43/7.50
(d, J=16.0 Hz, H-3) and 6.25/6.30 (d, J=16.0 Hz, H-2), as
well as multiplets of range d 6.70–7.10, assigned to aromatic
hydrogens H-5, H-8, and H-9, were observed. Additionally,
the spectrum of FA was observed to have an intense peak at
d 3.67, which was assigned to one methoxyl group. The 13C
NMR spectra of CA and FA also displayed signals ranging
from d 115 to d 150, corresponding to aromatic ring car-
bon atoms (C-1 to C-6), aliphatic sp2 carbon atoms at
d 116 (C-8) and d 145 (C-7), and one carboxyl group at
d 168 (C-9). With FA, an additional peak corresponding to
the methoxyl group linked to C-3 was observed at d 56.1.
LRESIMS showed a deprotonated ion (M-H)– peak at m/z
179 and 193, corresponding to the molecular formula
C9H8O4 and C10H10O4 of CA and FA, respectively. Following
analysis of our recorded data and of a description in the
literature (16), identification of CA and FA was achieved
(Figure 1).
HFD and combined treatment with caffeic
and ferulic acids
Keeping mice on HFD for 20 days increased caloric
intake (Figure 2A) and accelerated body weight gain
(Figure 2B and C). The combined treatment with CA and
FA was started on the 21st day of HFD after the establish-
ment of obesity. This regimen did not affect caloric intake
(Figure 2A) but it did prevent body weight gain associated
with HFD. Notably, the combined treatment reduced body
weight gain to levels below those observed in the Control
animals (Figure 2C). In addition, the fasting hyperglycemia
induced by HFD (223±17.9 vs Control 150±12.1 mg/dL,
with Po0.05) was improved with the combined treatment
with CA and FA (180±19.9 mg/dL) and normalized the
glucose intolerance caused by the HFD (Figure 3).
Investigation of the epididymal adipocyte area of the
animals is shown in Figure 4. Feeding on the HFD increased
the adipocyte area by approximately 2.5-fold whereas
combined treatment with both CA and FA prevented such
increase (Figure 4D). Brown adipose tissue was also studied
by assessing the UCP1 protein levels, but the elevation
Figure 1. Chemical structures of caffeic acid (CA) and ferulic acid
(FA), isolated from aerial parts of B. uncinella.
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caused by the HFD was similar in all groups despite
treatment with both CA and FA (Figure 5).
HFD induced liver steatosis in control animals but this
was prevented in the animals receiving combined treatment
with CA and FA (Figure 6A–C). In addition, animals on HFD
exhibited an elevation in plasma levels of cholesterol and
triglycerides, but this increase was also prevented by the
combined treatment with CA and FA (Table 2). These chang-
es in liver and serum lipids were mediated by modifications in
the key hepatic genes involved in lipid metabolism. Levels of
FAS mRNA are decreased in animals treated with CA and
FA. The gene expression for DGAT-2, the enzyme that
catalyzes the synthesis of triglycerides, was also reduced. In
addition, we also observed that the MTTP gene expression,
the protein that transfers triglycerides to VLDL molecules,
was significantly reduced by treatment with CA and FA. At
the same time, the adipose triacylglycerol lipase (ATGL)
mRNA levels increased with CA and FA treatment. This
combined treatment also increased PPAR-a mRNA levels,
but did not affect levels of mRNA for ChREBP or SREBP-1c
mRNA (Figure 6D).
The genes involved in cholesterol metabolism were also
evaluated. We found that the expression of SREBP-2, LXR
and LDL-R genes all increased with the combined treatment
of CA and FA. Unexpectedly, ACATand HMG-CoA reductase
mRNA levels were similar among the different groups in
contrast to the data showing that cholesterol synthesis was
inhibited by CA (Figure 6E).
Discussion
The present study shows that the combination therapy
with CA and FA in mice with HFD-induced metabolic
syndrome prevents obesity and reverts hyperglycemia,
Figure 3. Effect of a high-fat diet (HFD) with
combined treatment of caffeic acid (CA) and
ferulic acid (FA) (0.9 and 50 mg  kg–1  day–1,
respectively) on glucose metabolism. A, Blood
glucose levels before and after intraperitoneal
glucose tolerance test with administration of 2 g/kg
glucose. B, Area under curve (AUC) of the glu-
cose tolerance test (GTT) of all groups. Data are
reported as means±SEM of five animals per group.
*Po0.01 vs CTRL (ANOVA followed by the Student
Newman-Keuls test).
Figure 2. Effect of a high-fat diet (HFD) with combined treatment of caffeic acid (CA) and ferulic acid (FA) (0.9 and 50 mg  kg–1  day–1,
respectively) on diet-induced obesity. A, Caloric intake calculated from daily food consumption. B, Body weight (g). Arrows indicate when
the treatment with CA and FA was initiated. C, Body weight gain (DBW) after 40 days of treatment with CA and FA. Data are reported as
means±SEM of five animals per group. *Po0.01 control (CTRL) vs HFD (ANOVA followed by the Student Newman-Keuls test).
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dyslipidemia and hepatic steatosis, all conditions typically
observed in mice treated with HFD only. Previous studies
have shown that when used separately, CA prevented
HFD-induced glucose intolerance but failed entirely in
correcting obesity and dyslipidemia (6,9). Also, we found
that FA alone corrected the HFD-induced dyslipidemia but
failed to prevent obesity and glucose intolerance (10,11),
which is in contrast to a previous report (9). In addition,
studies have shown that treatment with either molecule
alone prevented HFD-induced liver steatosis (6,17).
The ability of both CA and FA to prevent HFD-induced
hypertriglyceridemia is remarkable and likely to involve i) a
direct liver effect to coordinate reduction in the FAS and
DGAT-2 expressions during HFD as well as to coordinate
the induction of ATGL and PPARa expression and/or ii) an
indirect effect mediated via prevention of obesity. Both CA
and FA have been reported to decrease FAS enzymatic
activity when administered separately (8–10). However, it
is conceivable that the beneficial effect of treatment with
CA on liver steatosis is predominantly indirect, via pre-
vention of obesity, even though treatment with CA has
previously been shown to induce PPARa in the liver (9).
Therefore, the mechanism by which CA and FA prevent
HFD-induced obesity remains to be clarified. Thermogen-
esis in brown adipose tissue does not seem to be involved
given that UCP-1 levels were not affected by treatment
with both molecules. The improvement in glucose toler-
ance is likely to be another byproduct of obesity pre-
vention given the known negative correlation between
obesity and insulin sensitivity.
The induction of the LDL-R, SREBP-2 and LXRamRNA
levels in liver by combined treatment with CA and FA is
striking. These changes suggest that both the uptake and
export of cholesterol in the liver were increased by the
action of CA and FA, resulting in increased flow of hepatic
cholesterol without causing hepatic steatosis and hypercho-
lesterolemia. This is in agreement with a previously re-
ported in vitro study showing that FA facilitates the capture
Figure 4. Effect of a high-fat diet (HFD) with
combined treatment of caffeic acid (CA) and
ferulic acid (FA) (0.9 and 50 mg  kg–1  day–1,
respectively) on histology of epididymal white
adipose tissue. A, Control (CTRL) mice; B, HFD
treated mice; C, HFD+CA+FA treated mice. All
magnifications are  200. Scale bar: 50 mm.
D, Estimated individual epididymal adipocyte
area; 40 cells for each animal (five animals per
group) were analyzed. ANOVA followed by the
Student Newman-Keuls test were used for
statistical analyses.
Figure 5. Effect of a high-fat diet (HFD) with combined treatment of
caffeic acid (CA) and ferulic acid (FA) (0.9 and 50 mg  kg–1 day–1,
respectively) on brown adipose tissue. A, UCP-1 by Western blotting
of all groups; B, UCP-1 expression performed by Western blotting of
all groups. Data are reported as means±SEM of five animals per
group ANOVA followed by the Student Newman-Keuls test were
used for statistical analyses.
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and degradation of LDL cholesterol by isolated hepato-
cytes (18). The increased expression of LXR stimulated
by the treatment of CA and FA suggests increased bile
acid synthesis. It is difficult to reconcile these results with
previous reports that suggest treatment with CA de-
creases the expression of SREBP-2 protein as assessed
by western blotting, which is not supported by the
elevation in LDL-R mRNA observed in the present study.
It is notable that in recent studies the combined treatment
with CA and FA failed to increase mRNA levels of
HMGCoA and ACAT1, especially as both molecules,
when administered separately, stimulate the expression
of these genes (8,9).
In conclusion, this study provides compelling experi-
mental evidence that combination therapy with CA and FA,
isolated from aerial parts of B. uncinellaC. DC. (Asteraceae),
is highly effective in preventing the multiple aspects of
metabolic syndrome in a HFD mouse model. The effects of
these molecules are likely to take place in the liver as
evidenced by changes in the expression of key genes
involved in lipid metabolism. In addition, it is likely that there
are direct effects of both molecules in the adipose tissue
because of their efficacy in reducing diet-induced obesity.
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Figure 6. Effect of a high-fat diet (HFD) with
combined treatment of caffeic acid (CA) and
ferulic acid (FA) (0.9 and 50 mg  kg–1  day–1,
respectively) on liver. Histology of liver stained
with hematoxylin and eosin from A, control (CTRL)
mice; B, HFD mice, arrows indicate the hepatic
steatosis; C, HFD+CA+FA mice. All magnifica-
tions are  200. Scale bar: 50 mm. D, Relative
mRNA analysis of genes related to triglyceride
metabolism: carbohydrate-responsive element-
binding protein (ChREBP); sterol regulatory ele-
ment-binding protein 1 (SREBP-1c); fatty acid
synthase (FAS); diacylglycerol O-acyltransferase
2 (DGAT-2); microsomal triglyceride transfer pro-
tein (MTTP); adipose triglyceride lipase (ATGL);
peroxisome proliferator-activated receptor alpha
(PPARa). E, Cholesterol metabolism: sterol reg-
ulatory element-binding protein 2 (SREBP-2); liver
X receptor alpha (LXR-a); low-density lipoprotein
receptor (LDL-R); acetyl-CoA acetyltransferase
1 (ACAT-1); 3-hydroxy-3-methyl-glutaryl-CoA reduc-
tase (HMG-CoA). Data are reported as means±
SEM of five animals per group. ANOVA followed
by the Student Newman-Keuls test were used for
statistical analyses.
Table 2. Cholesterol and triglycerides plasma levels of mice fed with chow diet
(Control), high-fat diet (HFD), and HFD with combined treatment of caffeic acid
(0.9 mg  kg–1 day–1; CA) and ferulic acid (50 mg  kg–1 day–1; FA) (HFD+CA+FA).
Parameter Control HFD HFD+CA+FA
Cholesterol (mg/dL) 74.6 ± 12.1 154.8 ± 19.5a 110.7 ± 7.3b
Triglycerides (mg/dL) 89.7 ± 12.2 130.8 ± 15.2a 93.5 ± 11.8b
Data are reported as means±SEM of 5 animals per group. aPo0.001 vs Control;
b Po0.01 vs HFD (ANOVA followed by the Student Newman-Keuls test).
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